Keensight Capital, a private equity company, agreed to acquire a majority stake in Symeres, a small molecule contract research and manufacturing organization, from Gilde Healthcare, a specialized healthcare investor. Financial terms were not disclosed. "With Keensight Capital’s investment, we plan to further extend and expand our range of drug discovery and development services. We believe that Keensight’s sector expertise and global reach will be a great asset to the company’s development. We are certain that our combined efforts will lead to an unmatched offering for our clients in the pharmaceutical and biotechnology industries,” Eelco Ebbers, Symeres Co-Founder and CEO.